Isotretinoin (Accutane)

The most potent oral retinoid achieving long-term remission of severe acne by fundamentally shrinking sebaceous glands

About This Treatment

Isotretinoin (13-cis-retinoic acid) is the global gold standard for severe nodular acne. A vitamin A derivative (retinoid) that addresses acne through four key mechanisms: sebaceous gland atrophy with up to 90% sebum suppression, normalization of follicular keratinization, anti-inflammatory effects via TLR2 downregulation, and indirect antibacterial action.

Not PMDA-approved in Japan (self-pay), but widely prescribed worldwide for treatment-resistant and scarring-risk acne. Achieving cumulative dose of 120-150mg/kg is key to long-term remission.

Mechanism of Action

①Sebaceous atrophy: RAR-mediated inhibition of basal sebocyte proliferation, up to 90% sebum suppression. Histologic gland shrinkage at 16 weeks, 30-80% activity reduction sustained 80+ weeks post-treatment. ②Keratinization normalization: corrects abnormal follicular keratinization, prevents comedone formation. ③Anti-inflammatory: downregulates TLR2, decreases IL-8, IL-36, TWEAK; inhibits Th17 responses. ④Indirect antibacterial: sebum reduction creates unfavorable environment for C. acnes (log3 reduction). ⑤Apoptosis: induces sebocyte-specific apoptosis, upregulates p53.

Indications

Expected Results

Initial improvement at 4-8 weeks, 85%+ clearance at 12-16 weeks, maximal effect at 16-20 weeks. 69% sustained remission at 10-year follow-up. Cumulative dose ≥120mg/kg: 26.9% relapse vs 47.4% below threshold (Lai et al., JAMA Dermatol 2025).

Clinical Evidence

Risks & Side Effects

Interested in this treatment?

Start with an AI skin analysis to check your current skin condition

Other Treatments